Search results
Merck (MRK) Begins Phase III NSCLC Study on KRAS Candidate
Zacks via Yahoo Finance· 2 months agoMerck MRK has initiated phase III study on its oral KRAS G12C inhibitor candidate, MK-1084, for...
After getting cancer in her 20s and then 70s, Joy Shapiro can attest to medical breakthroughs
Savannah Morning News via Yahoo News· 7 months agoJoy Shapiro underwent treatment for breast cancer in her 20s and then again in her 70s, making her a...
What Is Colorectal Cancer?
Verywell Health via Yahoo News· 1 year agoMedically reviewed by Jay N. Yepuri, MD Colorectal cancer is the uncontrolled growth of cells in the colon or rectum. It’s the fourth most common type of...
What Is Triple-Negative Breast Cancer?
Verywell Health via Yahoo News· 1 year agoTriple-negative breast cancer (TNBC) is a type of breast cancer that does not have hormone receptors. TNBC is diagnosed in 10% to 15% of all cases of...
Merck's Keytuda+Chemo Combo Improves Overall Survival In Patients With Advanced Mesothelioma
Benzinga via Yahoo Finance· 1 year agoMerck & Co Inc (NYSE: MRK) announced that the Phase 2/3 CCTG IND.227/KEYNOTE-483 trial of Keytruda...
Mirati's (MRTX) Krazati Gets Breakthrough Therapy Tag for CRC
Zacks via Yahoo Finance· 1 year agoThe FDA bestows a Breakthrough Therapy designation to Mirati's (MRTX) Krazati (adagrasib) for...
Everything You Need to Know About Melanoma Treatment
Verywell Health via Yahoo News· 12 months agoMelanoma is a cancer of the skin's pigment-producing cells known as the melanocytes. While it is not as common as other forms of skin cancer, it is the...
Bristol Myers says KRAS drug succeeds in key trial
BioPharma Dive via Yahoo Finance· 2 months agoConfirmatory results for Krazati, which Bristol Myers acquired via its buyout of Mirati, could help the drug win full approval while Amgen has been set...
Mirati (MRTX) Down 7% on CHMP's Opinion on Krazati Filing
Zacks via Yahoo Finance· 10 months agoPer the CHMP, Mirati's (MRTX) regulatory filing for Krazati in KRASG12C mutated NSCLC does not...
